Stephen LaMond
Chief Executive Officer at PEAK BIO, INC.
Net worth: 3 732 $ as of 2023-12-30
Profile
Stephen J.
LaMond is currently the CEO, COO, Secretary & Director at Peak Bio, Inc. and also holds the position of Chief Operating Officer at Peak Bio Co. Ltd.
Previously, he worked as the Director of Business Development & Marketing at Nektar Therapeutics, Vice President of Business Development at Corium International, Inc., Vice President of Marketing & Business Development at Aridis Pharmaceuticals, Inc., and Team Leader at Pfizer NV.
He completed his undergraduate degree at the University of Michigan.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PEAK BIO, INC.
0.09% | 2023-09-26 | 19,850 ( 0.09% ) | 3 732 $ | 2023-12-30 |
Stephen LaMond active positions
| Companies | Position | Start |
|---|---|---|
| PEAK BIO, INC. | Chief Executive Officer | 2022-10-31 |
Peak Bio Co. Ltd.
 Peak Bio Co. Ltd. BiotechnologyHealth Technology Part of Peak Bio, Inc., Peak Bio Co. Ltd. is a South Korean clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and inflammation. Peak Bio's location is in Seongnam, South Korea. The company's lead product candidate, php-303, is a small molecule currently in phase II clinical study for the orphan disease alpha1 anti-trypsin deficiency. Peak Bio has successfully completed phase I trials, demonstrating dose-dependent pharmacokinetics and establishing a dose for upcoming clinical trials. The company's cancer platform includes novel payloads and antibody-drug-conjugates (ADC) to address unmet needs in cancer care. The company was founded in 2015, and the CEO is Ho Young Huh. Peak Bio Co. was acquired by Ignyte Acquisition Corp. on November 01, 2022 for $353.84 million. | Chief Operating Officer | - |
Former positions of Stephen LaMond
| Companies | Position | End |
|---|---|---|
| CORIUM INTERNATIONAL INC | Corporate Officer/Principal | - |
| NEKTAR THERAPEUTICS | Sales & Marketing | - |
| Pfizer NV/SA | Corporate Officer/Principal | - |
| ARIDIS PHARMACEUTICALS, INC. | Sales & Marketing | - |
Training of Stephen LaMond
| University of Michigan | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ARIDIS PHARMACEUTICALS, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| PEAK BIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
| Pfizer NV/SA | |
Corium International, Inc.
 Corium International, Inc. Pharmaceuticals: MajorHealth Technology Corium International, Inc. is a pharmaceutical company. It offers products such as corplex donepezil and memantine. The company was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1999 and is headquartered in Menlo Park, CA. | Health Technology |
Peak Bio Co. Ltd.
Peak Bio Co. Ltd. BiotechnologyHealth Technology Part of Peak Bio, Inc., Peak Bio Co. Ltd. is a South Korean clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and inflammation. Peak Bio's location is in Seongnam, South Korea. The company's lead product candidate, php-303, is a small molecule currently in phase II clinical study for the orphan disease alpha1 anti-trypsin deficiency. Peak Bio has successfully completed phase I trials, demonstrating dose-dependent pharmacokinetics and establishing a dose for upcoming clinical trials. The company's cancer platform includes novel payloads and antibody-drug-conjugates (ADC) to address unmet needs in cancer care. The company was founded in 2015, and the CEO is Ho Young Huh. Peak Bio Co. was acquired by Ignyte Acquisition Corp. on November 01, 2022 for $353.84 million. | Health Technology |
- Stock Market
- Insiders
- Stephen LaMond
